| 000 | 03616cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032614.0 | ||
| 008 | 201017s2020 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.05.Ph.D.2020.Mu.T | ||
| 100 | 0 | _aMustafa Mohamed Selim | |
| 245 | 1 | 0 |
_aTherapy related late effects in pediatric patients with hodgkin lymphoma treated with ABVD protocol at national cancer institute, Cairo University and children cancer ospital Egypt 57357 / _cMustafa Mohamed Selim ; Supervised Mohamed Hani Hussein , Iman Abdelmokhales Sidhom , Zeinab Salah Selim |
| 246 | 1 | 5 | _aِِالأثار البعيدة المدى المرتبطة بعلاج الأطفال المصابين بورم هودجكين الغدد الليمفاوية وتم علاجهم ببرتوكول (إيه بى فى دى) فى المعهد القومى للأورام: جامعة القاهرة و مستشفى الأطفال مصر57573 |
| 260 |
_aCairo : _bMustafa Mohamed Selim , _c2020 |
||
| 300 |
_a280 P. : _bcharts , facimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric oncology | ||
| 520 | _aBackground/purpose Long-term Hodgkin Lymphoma (HL) survivors are at risk of developing a range of therapy-related complications that may present 10 -15 years after treatment. The primary goal of study is to estimate the frequency of late effects and to determine risk factors that may contribute to this. Methods We performed a cross-sectional study on HL survivors{u2019} who were treated at National Cancer Institute, Cairo or Children Cancer Hospital Egypt 57357 with ABVD chemotherapy ± radiotherapy with a minimum 5 years follow up. Results Two hundred and eight patients were candidate. The cumulative incidence (CI) of cardiac toxicity (CT) at 5 and 9 years was 18.7% ± SD 2.7 and 43.3% ± SD 4.4, respectively. Preexisting cardiac abnormalities, cumulative anthracycline dose and end of treatment cardiac status are a strong predictor for late cardiotoxicity. Hypertension, was observed in about 31% of HL survivors. Young age (prepuberty) and obesity at time of treatment are important factors for hypertension. Thyroid abnormalities developed with a 5-year CI of 2% (95% CI 0.6% - 4.9%) while at 9-years the CI was 27.9% (95% CI 19% - 36%). Neck radiation therapy and the percentage of thyroid gland exposed to radiation are important risk factors.Obesity, was observed in 36% of HL survivors. High body mass index and older age (post-puberty) at the initial presentation are significant factors for obesity during the follow up. Endocrine hypogonadism was present in 22.5% of male survivors and 38% of female survivors. Disturbance of menstrual cycles was XII present in about one-third of female survivors. Furthermore, exposure to radiation therapy was associated with higher risk of irregular menstrual cycles. Abnormal pulmonary function tests were found in 43% and restrictive pattern was the most common type. Secondary cancers were founded in 3 patients (1.4%) | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aDoxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) | |
| 653 | 4 | _aHodgkin Lymphoma survivors | |
| 653 | 4 | _aLate effects | |
| 700 | 0 |
_aIman Abdelmokhales Sidhom , _eSupervisor |
|
| 700 | 0 |
_aMohamed Hani Hussein , _eSupervisor |
|
| 700 | 0 |
_aZeinab Salah Selim , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c78251 _d78251 |
||